Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 2
2001 2
2002 2
2003 2
2004 1
2005 2
2006 7
2007 5
2008 2
2009 1
2011 1
2013 3
2015 1
2016 1
2017 1
2018 1
2019 1
2020 3
2021 1
2022 5
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S; PADA-1 investigators. Bidard FC, et al. Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1. Epub 2022 Sep 29. Lancet Oncol. 2022. PMID: 36183733 Clinical Trial.
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
Berger F, Marce M, Delaloge S, Hardy-Bessard AC, Bachelot T, Bièche I, Pradines A, De La Motte Rouge T, Canon JL, André F, Arnould L, Clatot F, Lemonnier J, Marques S, Bidard FC; PADA-1 investigators. Berger F, et al. BMJ Open. 2022 Mar 3;12(3):e055821. doi: 10.1136/bmjopen-2021-055821. BMJ Open. 2022. PMID: 35241469 Free PMC article. Clinical Trial.
[Health democracy: Patient partnership].
Haaser T, Constantinidès Y, Dejean C, Escande A, Le Tallec P, Lorchel F, Marty S, Thureau S, Huguet F, Lagrange JL; pour la Commission éthique de la SFRO. Haaser T, et al. Among authors: lorchel f. Cancer Radiother. 2020 Oct;24(6-7):736-743. doi: 10.1016/j.canrad.2020.06.021. Epub 2020 Aug 27. Cancer Radiother. 2020. PMID: 32861610 French.
[Ethical stakes in palliative care in radiation oncology].
Haaser T, Constantinides Y, Huguet F, De Crevoisier R, Dejean C, Escande A, Ghannam Y, Lahmi L, Le Tallec P, Lecouillard I, Lorchel F, Thureau S, Lagrange JL; pour la Commission Éthique de la SFRO. Haaser T, et al. Among authors: lorchel f. Cancer Radiother. 2021 Oct;25(6-7):699-706. doi: 10.1016/j.canrad.2021.07.004. Epub 2021 Aug 13. Cancer Radiother. 2021. PMID: 34400087 Review. French.
[Crisis situations: Ethical reflection on prioritization of care access in radiation oncology].
Haaser T, Constantinides Y, Lahmi L, Huguet F, de Crevoisier R, Dejean C, Escande A, Ghannam Y, Le Tallec P, Lorchel F, Mourman V, Thureau S, Lagrange JL; commission Éthique de la SFRO. Haaser T, et al. Among authors: lorchel f. Cancer Radiother. 2022 Oct;26(6-7):834-840. doi: 10.1016/j.canrad.2022.07.010. Epub 2022 Sep 6. Cancer Radiother. 2022. PMID: 36075833 Review. French.
Radiation and chemoradiation therapy for esophageal adenocarcinoma.
Bosset JF, Lorchel F, Mantion G, Buffet J, Créhange G, Bosset M, Chaigneau L, Servagi S. Bosset JF, et al. Among authors: lorchel f. J Surg Oncol. 2005 Dec 1;92(3):239-45. doi: 10.1002/jso.20365. J Surg Oncol. 2005. PMID: 16299784 Review.
[Radiotherapy for ovarian carcinoma management: Literature review].
Yossi S, Nguyen D, Khodri M, Reure J, Cervellera M, Lamberth F, Marchand V, Mammar V, Renoult F, Louet E, Coquard R, Barbet N, Lorchel F. Yossi S, et al. Among authors: lorchel f. Cancer Radiother. 2020 Apr;24(2):159-165. doi: 10.1016/j.canrad.2019.10.006. Epub 2020 Mar 6. Cancer Radiother. 2020. PMID: 32151544 French.
43 results